Fig. 6 | Nature Communications

Fig. 6

From: Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening

Fig. 6

Recurrent YAP1-MAML2 fusions activate Hippo pathway signaling. a YAP1-MAML2 fusions in patient tumours (left) and cell lines (right). b Interphase fluorescence in situ hybridization (FISH) (AM-38 only) targeting YAP1-MAML2 fusion (arrows; cells are polyploid with wild-type chromosomes circled) in AM-38, ES-2, and SAS cell lines. Probes used and chromosomal position are shown schematically. YAP1 and MAML2 are both on chromosome 11. c Fiber FISH showing gene fusion in AM-38, ES-2, and SAS cell lines. MAML2 probes are shown in green and blue; YAP1 probes are shown in white and red. d Schematic of YAP1-MAML2 and functional domains involved in the fusion. e Fold-change values of single guide RNAs (sgRNAs) targeting YAP1 and MAML2 genes in ES-2, AM-38, and SAS cell lines. f YAP1-MAML2 fusion-positive cell lines show the highest depletion of fusion-targeting MAML2 guides in ovary, head and neck, and glioblastoma cell lines (n = 54). Cell line in dark blue (H3118) harbors a known CRTC1-MAML2 fusion (Fig. 3c)22. g GSEA of YAP1 gene signature in YAP1-MAML2-positive cells (n = 3) vs. fusion-negative (n = 1008) cell lines. h Heatmap of 3345 fusion events tested in CRISPR and analysis of variance (ANOVA) systematic analyses. Fusions events are annotated if one of the partner genes is significantly overexpressed using our linear regression model, contain a COSMIC cancer driver gene, or has been detected in patient samples

Back to article page